Long-term study of indolent adult T-cell leukemia-lymphoma.
暂无分享,去创建一个
M. Tomonaga | T. Kohno | Yasuaki Yamada | M. Tawara | Y. Takasaki | S. Kamihira | K. Tsukasaki | Y. Miyazaki | M. Iwanaga | Y. Imaizumi | T. Joh | S. Ikeda
[1] K. Uozumi,et al. Smouldering adult T‐cell leukaemia/lymphoma: a follow‐up study in Kyushu , 2008, British journal of haematology.
[2] R. Ueda,et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Brites,et al. Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. , 2007, American journal of clinical pathology.
[4] M. Tomonaga,et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). , 2007, Leukemia research.
[5] M. Tomonaga,et al. Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. , 2006, Cancer letters.
[6] M. Tomonaga,et al. Possible origin of adult T‐cell leukemia/lymphoma cells from human T lymphotropic virus type‐1‐infected regulatory T cells , 2005, Cancer science.
[7] M. Tomonaga,et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma , 2005, Leukemia.
[8] M. Tomonaga,et al. Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes ("pre-ATL") in a 20-year follow-up study. , 2005, Blood.
[9] M. Tomonaga,et al. Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells , 2004, Journal of Virology.
[10] S. Iida,et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] M. Tomonaga,et al. Interruption of p16 gene expression in adult T‐cell leukaemia/lymphoma: clinical correlation , 2003, British journal of haematology.
[12] M. Tomonaga,et al. The Current Status of Therapy for Adult T-cell Leukaemia-Lymphoma in Japan , 2003, Leukemia & lymphoma.
[13] M. Stetler-Stevenson,et al. Adult T‐cell leukemia/lymphoma , 2002, Cancer.
[14] A. Bazarbachi,et al. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. , 2001, Virus research.
[15] F. Gheyas,et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.
[16] A. Jauch,et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. , 2001, Blood.
[17] M. Tomonaga,et al. A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.
[18] M. Setoyama,et al. Clinicopathologic Analysis of 124 Cases of Adult T‐Cell Leukemia/Lymphoma with Cutaneous Manifestations: The Smouldering Type with Skin Manifestations Has a Poorer Prognosis than Previously Thought , 1999, The Journal of dermatology.
[19] M. Tomonaga,et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Takatsuki,et al. Adult T-cell leukemia. , 1995, Internal medicine.
[21] A. Zuckerman,et al. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.
[22] E. Macintyre,et al. Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa , 1995 .
[23] K. Tsukasaki,et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. , 1993, Leukemia research.
[24] M. Shimoyama,et al. Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.
[25] K. Yamaguchi,et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[26] 松原 靖. Delineation of immunoregulatory properties of adult T cell leukemia cells , 2007 .
[27] K. Tobinai. CHEMOTHERAPY OF ATL , 2003 .
[28] Book review: Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses , 1997, Cancer Causes & Control.
[29] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Human Immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses. Lyon, France, 1-18 June 1996. , 1996, IARC monographs on the evaluation of carcinogenic risks to humans.
[30] Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987). , 1991, Leukemia research.
[31] M. Kikuchi,et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Y. Yamada. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. , 1983, Blood.